Wall Street Zen Downgrades ImageneBio (NASDAQ:IMA) to Sell

ImageneBio (NASDAQ:IMA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

ImageneBio Price Performance

ImageneBio stock opened at $5.29 on Friday. ImageneBio has a 12-month low of $3.94 and a 12-month high of $18.00. The firm’s fifty day moving average is $5.71 and its 200 day moving average is $6.60. The company has a market capitalization of $56.34 million, a PE ratio of -0.91 and a beta of 0.73.

ImageneBio (NASDAQ:IMA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25). Sell-side analysts expect that ImageneBio will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On ImageneBio

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC increased its stake in ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after purchasing an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of ImageneBio during the fourth quarter valued at about $76,000. Millennium Management LLC bought a new stake in shares of ImageneBio during the fourth quarter worth about $79,000. T3 Companies LLC bought a new stake in shares of ImageneBio during the fourth quarter worth about $91,000. Finally, Jane Street Group LLC acquired a new stake in shares of ImageneBio in the 4th quarter worth about $103,000. Institutional investors own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.